Susannah G. Ellsworth

Susannah G. Ellsworth

Auto-generated profile, based on publicly available information

Susannah G. Ellsworth

Radiation Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Advances in Radiation Oncology
Verified
Journal Article
Open access
SESusannah G. Ellsworth
Susannah G. Ellsworth
Radiation-induced lymphopenia (RIL) is the result of direct toxicity to circulating lymphocytes as they traverse the irradiated field, occurs in 40% to 70% of patients who undergo conventional external beam radiation therapy, and is associated with worse outcomes in multiple solid tumors. As immunotherapy strategies evolve, a better understanding of radiation's effects on the immune system is needed in order to develop rational methods of combining RT with immunotherapy. This paper is a review of the available literature on the clinical significance and dosimetric predictors of radiation-induced toxicity to the immune system. An association between severe RIL and inferior survival has been described in multiple solid tumors, including glioma, lung cancer, and pancreatic cancer. RIL risk is correlated with field size, dose per fraction, and fraction number. SBRT and proton therapy techniques are associated with lower RIL risk. The immune system should be considered an organ at risk during RT, and absolute lymphocyte count is an important biomarker of RT-induced immunotoxicity. Radiation dose and technique affect the risk and severity of RIL. Further research is needed to accurately characterize RT-induced immunotoxicity and develop strategies to prevent or mitigate this clinically significant side effect.

8 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
JJJian-Yue Jin
Jian-Yue Jin
CHChen Hu
Chen Hu
YXYing Xiao
Ying Xiao
HZHong Zhang
Hong Zhang
RPRebecca Paulus
Rebecca Paulus
FKFeng-Ming Kong
Feng-Ming Kong
Background: We hypothesized that the Effective radiation Dose to the Immune Cells (EDIC) in circulating blood is a significant factor for the treatment outcome in patients with locally advanced non-small-cell lung cancer (NSCLC). Methods: This is a secondary study of a phase III trial, NRG/RTOG 0617, in patients with stage III NSCLC treated with radiation-based treatment. The EDIC was computed as equivalent uniform dose to the entire blood based on radiation doses to all blood-containing organs, with consideration of blood flow and fractionation effect. The primary endpoint was overall survival (OS), and the secondary endpoints were progression-free survival (PFS) and local progression-free survival (LPFS). The EDIC–survival relationship was analyzed with consideration of clinical significant factors. Results: A total of 456 patients were eligible. The median EDIC values were 5.6 Gy (range, 2.1–12.2 Gy) and 6.3 Gy (2.1–11.6 Gy) for the low- and high-dose groups, respectively. The EDIC was significantly associated with OS (hazard ratio [HR] = 1.12, p = 0.005) and LPFS (HR = 1.09, p = 0.02) but PFS (HR = 1.05, p = 0.17) after adjustment for tumor dose, gross tumor volume and other factors. OS decreased with an increasing EDIC in a non-linear pattern: the two-year OS decreased first with a slope of 8%/Gy when the EDIC < 6 Gy, remained relatively unchanged when the EDIC was 6–8 Gy, and followed by a further reduction with a slope of 12%/Gy when the EDIC > 8 Gy. Conclusions: The EDIC is a significant independent risk factor for poor OS and LPFS in RTOG 0617 patients with stage III NSCLC, suggesting that radiation dose to circulating immune cells is critical for tumor control. Organ at risk for the immune system should be considered during RT plan.

1 March 2020 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
JJJian-Yue Jin
Jian-Yue Jin
TMTodd Mereniuk
Todd Mereniuk
AYAnirudh Yalamanchali
Anirudh Yalamanchali
WWWeili Wang
Weili Wang
MMMitchell Machtay
Mitchell Machtay
SESusannah Ellsworth
Susannah Ellsworth

3 July 2023 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
SESusannah G. Ellsworth
Susannah G. Ellsworth
PRPeter S.N. van Rossum
Peter S.N. van Rossum
RMRadhe Mohan
Radhe Mohan
SLSteven H. Lin
Steven H. Lin
CGClemens Grassberger
Clemens Grassberger
BHBrian Hobbs
Brian Hobbs

1 November 2019 in Radiation Research
Verified
Journal Article
Closed access
SESusannah G. Ellsworth
Susannah G. Ellsworth
AYAnirudh Yalamanchali
Anirudh Yalamanchali
HZHong Zhang
Hong Zhang
SGStuart A. Grossman
Stuart A. Grossman
RHRobert Hobbs
Robert Hobbs
JJJian-Yue Jin
Jian-Yue Jin
Radiation-induced lymphopenia (RIL) is associated with worse survival in patients with solid tumors, as well as lower response rates to checkpoint inhibitors. While single-fraction total-body irrad...

8 April 2022 in Advances in Radiation Oncology
Verified
Journal Article
Open access
SESusannah G. Ellsworth
Susannah G. Ellsworth
AYAnirudh Yalamanchali
Anirudh Yalamanchali
TLTim Lautenschlaeger
Tim Lautenschlaeger
SGStuart A. Grossman
Stuart A. Grossman
CGClemens Grassberger
Clemens Grassberger
RMRadhe Mohan
Radhe Mohan
Radiation causes exponential depletion of circulating lymphocyte populations; in turn, radiation-induced lymphopenia is associated with worse survival for many solid tumors, possibly owing to attenuated antitumor immune responses. Identifying reliable and reproducible methods of calculating the radiation dose to circulating immune cells may facilitate development of techniques to reduce the risk and severity of radiation-induced toxic effects to circulating lymphocytes. Patient-specific lymphocyte loss rates were derived from a clinical data set including 684 adult patients with solid tumors. Multivariable linear regression was used to model the relationship between the lymphocyte loss rate and physical parameters of the radiation plan that determine circulating blood dose. During partial-body radiation, lymphocyte loss rates are determined by physical parameters of the radiation plan that reflect radiation exposure to circulating cells, including target volume size, dose per fraction squared, and anatomic site treated. Differences in observed versus predicted lymphocyte loss rates may be partly explained by variations in concurrent chemotherapy regimens. We describe a novel method of using patient-specific lymphocyte loss kinetics to approximate the effective radiation dose to circulating lymphocytes during focal fractionated photon radiation therapy. Clinical applications of these findings include the early identification of patients at particularly high risk of severe radiation-induced lymphopenia based on physical parameters of the radiation therapy plan.